DigiNepal

Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer

Oncology Research · Xiaojing Liu, Beibei Hua, Yang Xia et al. · 2026

  • EnglishRead in your language
  • CitedEvery fact sourced
  • Ad-freeNo ads, no tracking

Quick facts

Author
Xiaojing Liu, Beibei Hua, Yang Xia, Huijie Huang, Areai Hakewati, Zeze Jin, Tumaris Halifu, Zaihua Xu ref
Published
ref
Publisher
Tech Science Press ref
Journal
Oncology Research ref

Questions

Who wrote Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer?
Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer was written by Xiaojing Liu, Beibei Hua, Yang Xia, Huijie Huang.
When was Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer first published?
Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer was first published in 2026.

Sources

  1. Publisher record (DOI, via Crossref)

Last updated · facts checked 27 October 2026

Cite this page

"Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer". DigiNepal. Last updated 27 October 2026. https://diginpl.com/books/paper-or-2026-088774. Retrieved 14 November 2026.

Machine-readable versions: JSON · Markdown

Open-access publication. Read it free at the publisher: https://doi.org/10.32604/or.2026.088774.

← Books